Digestive Health & Gastroenterology Clinical Trials Update: Week 25, 2026

Published June 19, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis

This Phase 3 trial is exploring the use of filgotinib, an oral medication, for children and teenagers aged 8 to under 18 with moderately to severely active ulcerative colitis. If successful, this treatment could offer a simpler way to manage symptoms compared to current options, making it easier for young patients to take their medicine regularly. The study is ongoing across several countries and aims to improve quality of life for young people living with this condition.

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

This Phase 3b study is focused on the long-term safety of vedolizumab, a treatment given by injection, in children and teenagers with ulcerative colitis or Crohn's disease. The trial follows young patients who have previously responded well to vedolizumab to see if ongoing treatment can reduce hospital visits and help maintain symptom control. Recruitment is underway in Japan, offering valuable information about managing these chronic digestive diseases over time.

Long Term Outcomes of Bariatric Patients Treated With Surgery or Endoscopy

This study examines the effects of surgical and endoscopic treatments for gastroesophageal reflux disease (GERD) in people with obesity. By tracking how often GERD returns after these procedures, the research aims to guide better treatment choices in the future. The trial is active in the United States and is enrolling around 250 participants to gather detailed long-term outcomes.

Comparative Effectiveness of Upadacitinib vs Corticosteroids as First-Line Therapy for Acute Severe Ulcerative Colitis (UPFRONT)

This Phase 4 trial compares the daily medication upadacitinib with corticosteroids as the first treatment for adults experiencing acute severe ulcerative colitis. The goal is to see if upadacitinib can be as effective as steroids while potentially offering a different side effect profile. Conducted in China, the study involves 46 participants over three months and could expand options for managing this serious condition.

Vancomycin Efficacy in Response to Dysbiosis in Atypical Colitis

This Phase 2 trial investigates whether adding oral vancomycin to standard care helps children with pediatric inflammatory bowel diseases, including ulcerative colitis and primary sclerosing cholangitis-related colitis. The study, taking place in Finland, aims to improve disease remission rates and gut health by addressing imbalances in gut bacteria. Participants will be closely monitored over up to 12 months with regular clinic visits and sample collections.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.